Qyuns Therapeutics says China clears QX027N trials for COPD

• China’s NMPA drug review center cleared QX027N clinical trials in COPD and chronic rhinosinusitis with nasal polyps.
• The approvals add two respiratory indications to the bispecific antibody program, following atopic dermatitis and asthma.
• Phase II studies in China for multiple indications are slated to start in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12264780), on July 31, 2026, and is solely responsible for the information contained therein.